This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Part 1. Gefitinib and Erlotinib for Non-Small Cell Lung Cancer
The technology assessment program
at the Agency for Healthcare Research and Quality (AHRQ) provides technology
assessments for the Centers for Medicare & Medicaid Services (CMS). These
technology assessments are used by CMS to inform its national coverage
decisions for the Medicare program as well as provide information to Medicare
AHRQ's technology assessment program uses state-of-the-art methodologies for assessing the clinical utility of medical interventions. Technology assessments are based on a systematic review of the literature, along with appropriate qualitative and quantitative methods of synthesizing data from multiple studies.
Select for PDF Version (350 KB). PDF Help.
Prepared for AHRQ under Contract No. 290-02-0025. By Michael
J. Kelley, M.D., and Douglas C. McCrory, M.D., M.H.S., Duke Evidence-based
Practice Center, Center for Clinical Health Policy Research.
Current as of November 2005